What is Apriori Bio?
Apriori Bio, a Boston-based biotechnology firm, is at the forefront of combating viral threats through innovative vaccine design. Leveraging a proprietary technology platform, the company analyzes the full spectrum of viral variants to engineer resilient vaccines. Founded by Flagship Pioneering, Apriori Bio aims to provide humanity with robust protection against rapidly mutating viruses, addressing a critical global health challenge.
How much funding has Apriori Bio raised?
Apriori Bio has raised a total of $1.1M across 1 funding round:
Other Financing Round
$1.1M
Other Financing Round (2024): $1.1M with participation from Cepi Centre Enseignement Publications Informatiques
Key Investors in Apriori Bio
Cepi Centre Enseignement Publications Informatiques
Cepi Centre Enseignement Publications Informatiques, based in France, operates within the publishing sector. Its involvement suggests a potential interest in the dissemination of scientific advancements or the strategic application of research findings.
What's next for Apriori Bio?
The substantial enterprise-level funding indicates Apriori Bio is poised for significant scaling and further development of its variant-resilient vaccine technology. This capital injection will likely accelerate research and development, clinical trials, and strategic partnerships, positioning the company to address emerging viral pandemics and strengthen global health security.
See full Apriori Bio company page
